Kageaki Watanabe

High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer

Yusuke Okuma, Yukio Hosomi, Yoshiro Nakahara et al. · Lung Cancer · 2016 · 175 citations

Prognostic Biomarkers, Advanced Lung Cancer, Medicine +12

Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors

Yasuhiro Kato, Yukio Hosomi, Kageaki Watanabe et al. · Journal of Thoracic Disease · 2019 · 54 citations · Full text

Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center

Yusuke Okuma, Yukio Hosomi, Kageaki Watanabe et al. · BMC Cancer · 2014 · 32 citations · Full text

Management of Cardiac Tamponade During Nivolumab Of Lung Cancer with Intrapericardial Bleomycin: Case Report

Maiko Asai, Yasuhiro Kato, Shoko Kawai et al. · Immunotherapy · 2019 · 26 citations · Full text

Medicine, Pathology, Advanced Lung Adenocarcinoma +11

Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer

Hiroaki Okamoto, Kageaki Watanabe, Yoshihiko Segawa et al. · International Journal of Clinical Oncology · 2000 · 25 citations

Medicine, Metronomic Therapy, Phase Ii Study +6